Corvus Pharmaceuticals, Inc. - Common Stock (CRVS)
5.5000
+0.2100 (3.97%)
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on the development of innovative therapies for the treatment of cancer
The company is primarily engaged in the discovery and development of immuno-oncology products, aiming to harness the body’s immune system to fight against various types of tumors. Corvus leverages its expertise in biologic compounds to create targeted treatments that enhance immune response while minimizing side effects. Through its ongoing research and clinical trials, the company seeks to provide new options for patients with unmet medical needs in oncology.
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSETME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million.
Shares of Green Giant Inc. (NASDAQGGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some other stocks moving in pre-market trading.
